Wolverine Blend BPC-157 10mg + TB500 10mg

Wolverine Blend is suited for research teams investigating multi-pathway peptide interaction dynamics where simultaneous modulation of distinct molecular targets is required within a single experimental protocol. Laboratories studying BPC-157’s activity on vascular endothelial signaling and gastrointestinal mucosal pathway markers alongside TB500’s role in actin cytoskeletal regulation and cell migration endpoint quantification will find the fixed-ratio format practical for combination study designs. The 10mg:10mg configuration provides sufficient material for extended multi-phase protocols without requiring separate vial management for each component. Produced by Elivena in USA GMP-certified facilities, each vial is COA-verified for purity and sequence identity across both peptides.

Multi-Pathway Signaling Interaction Studies

Wolverine Blend enables research teams to examine whether simultaneous activation of BPC-157-associated endothelial and gastrointestinal signaling pathways and TB500-associated cytoskeletal and cell migration pathways produces measurable interaction effects on shared downstream molecular markers. This design supports investigation of peptide combination effects on VEGF pathway activity, actin polymerization dynamics, and angiogenic assay endpoints in controlled in-vitro and preclinical in-vivo models.

Angiogenic Marker and Endothelial Signaling Research

Both components have been independently studied in relation to angiogenic signaling endpoint activity. Wolverine Blend supports research examining whether dual-peptide administration influences endothelial tube formation assay parameters, VEGF receptor interaction dynamics, and angiogenic marker expression patterns differently than single-peptide protocols — contributing to mechanistic understanding of peptide combination effects on vascular signaling biology.

Cytoskeletal Dynamics and Cell Migration Endpoint Quantification

TB500’s actin-sequestering activity makes Wolverine Blend relevant for studies examining cytoskeletal regulatory marker expression, directional cell migration assay outcomes, and extracellular matrix remodeling endpoint quantification. Combination with BPC-157 allows researchers to investigate whether endothelial and gastrointestinal signaling pathway activity modulates cell migration endpoint parameters in shared tissue model systems.

Preparation Guidelines

Reconstitute lyophilized Wolverine Blend with sterile bacteriostatic water using standard sterile laboratory technique. Reconstitution volume should be determined based on the target experimental concentration for each component as specified by the study design. Both peptides are present in equal quantities; researchers requiring independent dosing of each component should use separately sourced vials of BPC-157 and TB500. Use calibrated laboratory equipment for all preparation and handling steps.

Storage Conditions

Store lyophilized blend at 2–8°C, protected from light and moisture, prior to reconstitution. Following reconstitution, maintain refrigeration at 2–8°C and use within the timeframe specified in the laboratory protocol. Lyophilized material does not require cold-chain shipping but should be refrigerated upon receipt to preserve the integrity of both peptide components. Each Elivena vial is supplied with COA documentation and handling guidance for dual-peptide formulations.

USA GMP Manufacturing by Elivena

Both components are manufactured by Elivena in USA GMP-certified facilities to approximately 99% purity, verified by independent third-party COA documentation. Each vial confirms peptide sequence identity and purity grade for both BPC-157 and TB500, providing laboratories with consistently characterized dual-peptide material for advanced multi-pathway signaling research.

• CAS: BPC-157: 137525-51-0 / TB500: 885340-08-9
• Chemical Formula: BPC-157: C₆₂H₉₈N₁₆O₂₂ TB500: C₃₈H₆₈N₁₀O₁₄
• Molecular Weight: BPC-157: 1419.535 g/mol TB-500(TB-4): 889.0 g/mol
• Peptide Sequence: BPC157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; TB-500(TB4): Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
• Shelf life: 24 months from the manufacturing date.

Dual-Peptide Structural Profile

Wolverine Blend combines BPC-157 — a synthetic pentadecapeptide derived from a gastric protein sequence — with TB500, a synthetic analog of Thymosin Beta-4 (Tβ4). These two peptides are structurally unrelated and operate through distinct molecular mechanisms, making their combination relevant for researchers examining whether complementary pathway activation produces additive or synergistic effects on shared downstream signaling endpoints. Their structural distinction supports controlled mechanistic dissection of individual vs. combined pathway contributions within the same experimental model.

BPC-157 Molecular Activity Profile

BPC-157 is studied for its interaction with vascular endothelial growth factor (VEGF) signaling pathways, nitric oxide system activity, and gastrointestinal mucosal cellular signaling in preclinical models. Researchers use it to examine angiogenic marker expression, endothelial cell signaling dynamics, and mucosal histological endpoint progression. Its stable gastric pentadecapeptide structure supports reproducible in-vitro and in-vivo preclinical study designs across multiple tissue model systems.

TB500 Molecular Activity Profile

TB500 — a Thymosin Beta-4 analog — is studied for its role in actin cytoskeletal regulation, cell migration assay endpoints, and angiogenic signaling pathway activity. Tβ4 sequesters G-actin monomers, influencing cytoskeletal dynamics and downstream cellular motility marker expression. Researchers use TB500 to examine peptide-mediated modulation of cell migration parameters, endothelial tube formation assays, and extracellular matrix interaction dynamics in controlled preclinical settings.

USA GMP Manufacturing by Elivena

Both components are manufactured by Elivena in USA GMP-certified facilities to approximately 99% purity, verified by independent third-party COA documentation. Each vial confirms peptide sequence identity and purity grade for both BPC-157 and TB500, providing laboratories with consistently characterized dual-peptide material for advanced multi-pathway signaling research.

BPC-157 is studied primarily for its interaction with VEGF signaling pathways, nitric oxide system activity, and gastrointestinal mucosal cellular signaling markers. TB500 is studied for its role in G-actin sequestration, cytoskeletal regulatory dynamics, and cell migration endpoint modulation. Their structural and mechanistic distinction makes them complementary subjects for multi-pathway combination research designs.

Yes. Researchers requiring independent dosing or ratio adjustment of each component should source BPC-157 and TB500 as separate vials. The Wolverine Blend fixed 10mg:10mg format is suited to combination study designs where equal concentrations of both peptides are experimentally appropriate.

The equal ratio provides sufficient material of each peptide to investigate complementary molecular pathway activity within a single protocol, without prioritizing one component’s signaling contribution over the other. Researchers with study designs requiring differential concentration ratios should use independently sourced vials of each compound.